{"id":"liraglutide-orlistat","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"15-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Abdominal pain"},{"rate":"10-25","effect":"Oily spotting or fecal urgency"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL175247","moleculeType":"Small molecule","molecularWeight":"495.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide is a GLP-1 receptor agonist that enhances postprandial insulin secretion, slows gastric emptying, and promotes satiety through central nervous system effects. Orlistat is a lipase inhibitor that blocks the absorption of approximately 25-30% of dietary fat in the gastrointestinal tract. Together, they provide complementary mechanisms for weight loss and glycemic control.","oneSentence":"Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:03.274Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Weight management in obese or overweight patients"},{"name":"Type 2 diabetes mellitus with obesity"}]},"trialDetails":[{"nctId":"NCT07301437","phase":"PHASE4","title":"RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"Overweight and Obese Adults","enrollment":120},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT05812183","phase":"PHASE4","title":"Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-07-09","conditions":"Dyspnea, Quality of Life","enrollment":""},{"nctId":"NCT04531176","phase":"PHASE4","title":"EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-09-01","conditions":"Type 2 Diabetes, Obesity","enrollment":74},{"nctId":"NCT06501326","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2023-11-01","conditions":"Non-alcoholic Fatty Liver Disease, Obesity","enrollment":102},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT02041234","phase":"PHASE4","title":"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-02","conditions":"Type II Diabetes in Subjects BMI 27 to 32","enrollment":40},{"nctId":"NCT04417582","phase":"","title":"Life Style Modification Medical and Surgical Management in Patients With Obesity","status":"UNKNOWN","sponsor":"Marmara University","startDate":"2020-01-01","conditions":"Obesity, Weight Change, Body, Obesity; Endocrine","enrollment":1000},{"nctId":"NCT01597531","phase":"PHASE4","title":"Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding","status":"TERMINATED","sponsor":"East Carolina University","startDate":"2012-06","conditions":"Type 2 Diabetes, Gastric Banding","enrollment":1},{"nctId":"NCT00422058","phase":"PHASE2","title":"The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01-10","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":564}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":238,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Liraglutide + Orlistat","genericName":"Liraglutide + Orlistat","companyName":"East Carolina University","companyId":"east-carolina-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption. Used for Obesity and weight management, Type 2 diabetes mellitus with obesity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}